|Videos|May 25, 2022
Prostate Cancer Management: Future Directions in Care
Closing out their discussion on the management of prostate cancer, panelists consider remaining unmet needs and future directions in care.
Advertisement
Episodes in this series
Advertisement
Related to this article
CHMP has recommended EU approval of senaparib for advanced ovarian cancer based on FLAMES data.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
The FDA approved imlunestrant/abemaciclib for ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after progression on endocrine therapy.
Roswell Park Comprehensive Cancer Center unveiled a new and more compact mobile lung cancer screening unit.
The CHMP recommended approval of adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease after neoadjuvant therapy.
Udai S. Kammula, MD, FACS, discusses TIL therapy outcomes, the UMIS biomarker, and treatment implications in metastatic uveal melanoma.
CHMP has recommended EU marketing authorization for relacorilant combined with nab-paclitaxel in platinum-resistant ovarian cancer.
The positive CHMP opinion for teclistamab in second- and later-line relapsed/refractory multiple myeloma is supported by MajesTEC-9 data.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Imlunestrant Plus Abemaciclib for ER+, HER2–, ESR1-Mutated Metastatic Breast Cancer
2
CHMP Recommends Label Expansion of Melflufen to Third-Line Lenalidomide-Refractory Multiple Myeloma
3
Phase 1 Data Support DAWN-303’s Evaluation of INCB161734 in Frontline KRAS G12D–Mutated PDAC
4
Tumor-Reactive TIL and UMIS Biomarker Predict Response in Metastatic Uveal Melanoma
5